Emerging Trends Influencing The Growth Of The Diverticulitis Disease Market: Innovative Drug Development Spurs Advances In Diverticulitis Treatments

The Diverticulitis Disease Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

How Big Is the Diverticulitis Disease Market Size Expected to Be by 2034?
The market size of diverticulitis disease has experienced a swift expansion in recent times. It is expected to increase from $1.85 billion in 2024 to $2.04 billion in 2025 with a compound annual growth rate (CAGR) of 10.1%. The acceleration in growth during the historical timeframe is due to factors such as the aging population, changing dietary habits, obesity rates, and advancements in medical imaging technologies.

In the coming years, substantial progress is anticipated in the diverticulitis disease market, with predictions suggesting a surge to $2.92 billion by 2029, following a compound annual growth rate (CAGR) of 9.4%. This predicted growth during the forecast period can be credited to factors such as colonoscopy and endoscopy, heightened awareness, less aggressive medical procedures, and individualized treatment methods. The trending practices during this forecast period would involve preventive approaches, improved diagnostic instruments, team-based care models, and modifications in healthcare policies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12990

What Are the Emerging Segments Within the Diverticulitis Disease Market?
The diverticulitis disease market covered in this report is segmented -

1) By Type: Uncomplicated, Complicated
2) By Diagnosis: Computed Tomography (CT) Scan, Ultrasound, Urine Test, Blood Test
3) By Treatment: Medications, Surgery, Supportive care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (IV) Fluids
4) By End-User: Specialty Centers, Hospitals, Research centers

Subsegments:
1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy
2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

What Long-Term Drivers Are Shaping Diverticulitis Disease Market Trends?
The growth of the diverticulitis disease market is anticipated to be fueled by the increasing rates of smoking addiction. Inserts such as widespread promotion, societal acceptance, stress, and nicotine's addictive properties have spearheaded the boom in smoking habits. The emergence of e-cigarettes and vaping devices along with societal influences and peer pressure, especially among the young, further intensify the increase in smoking. Smoking aggravates the scenario in the diverticulitis treatment space by escalating the chances of diverticular disease through impaired colon blood flow, leading to more critical problems. This, in turn, results in an increased need for diagnosing and medicinal alternatives. For instance, as per Statistics Canada, in July 2022, there was a 5.8% hike in cigarette production when compared to June 2021. Also, there was a 1.3% increase from May 2022 in complete cigarette sales amounting to 1.4 billion by June 2022. Hence, the escalating smoking addiction rates are expected to catalyze the diverticulitis disease market's progress. The growing incidences of diabetes are predicted to push the diverticulitis disease market's upgrade. The key drivers behind the rise in diabetes cases involve unhealthy dietary habits with processed foods, a static lifestyle, an increase in obesity, genetic factors, and an aging demography. Diabetes heightens the hazard of complications such as weakened blood vessels that increase the vulnerability of the colon to infections and inflammation, thereby resulting in a bigger demand for treatments. For instance, The National Health Service (NHS England) revealed that in 2023, the figure of pre-diabetes patients recognized by the NHS in England jumped by 18% to 3,615,330 from 3,065,825 in 2022. Furthermore, in those below 40, the cases surged approximately 25% growing from 173,166 in 2022 to 216,440 in 2023. Hence, the growing prevalence of diabetes propels the diverticulitis disease market.

Who Are the Top Competitors in Key Diverticulitis Disease Market Segments?
Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

What Diverticulitis Disease Market Trends Are Gaining Traction Across Different Segments?
Major firms in the diverticulitis disease market are focusing on creating innovative drugs and achieving regulatory approval to maintain their market standing. This focus on drug development could pave the way for more effective diverticulitis treatments, minimizing complication risks and improving patient recoveries. For example, Seres' microbiota medication, designed to treat recurrent gut infections and prevent Clostridioides difficile (C. diff.) infections from recurring in adults 18 years and older, was approved by the US-based federal organization, the United States Food and Drug Administration, in April 2023. The approval of Vowst came after a clinical trial involving 346 patients with recurrent CDI, where it was found that those who took Vowst experienced significantly fewer recurrences of the infection compared to those given a placebo. It is an orally-administered drug derived from microbiota containing Firmicutes spores, which are attributed to a healthy microbiome capable of resisting C. diff. colonization.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Which Regions Are Becoming Hubs for Diverticulitis Disease Market Innovation?
North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Diverticulitis Disease Market?
2. What is the CAGR expected in the Diverticulitis Disease Market?
3. What Are the Key Innovations Transforming the Diverticulitis Disease Industry?
4. Which Region Is Leading the Diverticulitis Disease Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.